

Supplementary Materials for
Consolidated Financial Results
for the 3rd Quarter of Fiscal Year 2012. 12



CHUGAI PHARMACEUTICAL CO., LTD.



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in Financial Highlights, Statements of Revenues, Balance Sheets, Cash Flows and Capital Expenditures of this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

(Yen)

Fx rates	FY2009	FY2010	FY2011				FY2012				Forecast (Feb 1 st announced)
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2012
	(Full-year)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(Full-year)
	average	average	average	average	average	average	average	average	average	average	forecast
CHF	86.20	84.17	87.30	90.38	91.62	89.86	86.01	85.82	84.43	—	85.00
EUR	130.10	116.32	112.36	114.86	113.25	110.92	103.91	103.39	101.69	—	109.00
USD	93.60	87.81	82.23	81.93	80.55	79.75	79.26	79.71	79.35	—	82.00

Financial Highlights (YTD)

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012								Forecast (Feb 1 st announced)			
			FY2011				FY2012								FY2012			
			1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-6	Change (%)	1-12	Change (%)
			YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		Half-year(Actual)		Full-year	
Revenues	428.9	379.5	85.7	181.9	276.0	373.5	90.3	+5.4	185.3	+1.9	275.4	(0.2)	—	—	185.3	+1.9	418.5	+12.0
Sales	419.1	375.6	80.4	174.8	267.5	363.6	86.8	+8.0	180.0	+3.0	268.6	+0.4	—	—	180.0	+3.0	403.7	+11.0
excl. Tamiflu	342.9	357.4	76.2	170.2	261.2	354.9	79.0	+3.7	171.9	+1.0	260.4	(0.3)	—	—	171.9	+1.0	394.1	+11.0
Tamiflu	76.2	18.2	4.2	4.6	6.3	8.7	7.8	+85.7	8.1	+76.1	8.2	+30.2	—	—	8.1	+76.1	9.6	+10.3
Ordinary sales	36.2	1.6	3.7	4.1	4.1	5.4	7.5	+102.7	7.8	+90.2	7.9	+92.7	—	—	7.8	+90.2	9.3	+72.2
Govt. stockpile etc.	40.0	16.6	0.5	0.5	2.2	3.3	0.4	(20.0)	0.4	(20.0)	0.4	(81.8)	—	—	0.4	(20.0)	0.3	(90.9)
Other operating revenues	9.8	3.9	5.3	7.2	8.5	9.9	3.5	(34.0)	5.3	(26.4)	6.8	(20.0)	—	—	5.3	(26.4)	14.8	+49.5
Cost of sales	192.9	162.4	35.1	74.5	115.4	157.5	39.6	+12.8	81.7	+9.7	121.0	+4.9	—	—	81.7	+9.7	178.5	+13.3
(% of Sales)	46.0	43.2	43.7	42.6	43.1	43.3	45.6	—	45.4	—	45.0	—	—	—	45.4	—	44.2	—
Gross profit	236.1	217.1	50.6	107.4	160.7	216.0	50.6	+0.0	103.5	(3.6)	154.4	(3.9)	—	—	103.5	(3.6)	240.0	+11.1
(% of Revenues)	55.0	57.2	59.0	59.0	58.2	57.8	56.0	—	55.9	—	56.1	—	—	—	55.9	—	57.3	—
SG&A (excl. R&D) expenses	98.2	96.2	22.0	45.3	69.4	97.7	21.0	(4.5)	43.0	(5.1)	66.1	(4.8)	—	—	43.0	(5.1)	100.0	+2.4
(% of Revenues)	22.9	25.3	25.7	24.9	25.1	26.2	23.3	—	23.2	—	24.0	—	—	—	23.2	—	23.9	—
R&D expenses	55.3	54.7	13.0	26.9	41.2	55.9	13.1	+0.8	26.2	(2.6)	40.0	(2.9)	—	—	26.2	(2.6)	60.0	+7.3
(% of Revenues)	12.9	14.4	15.2	14.8	14.9	15.0	14.5	—	14.1	—	14.5	—	—	—	14.1	—	14.3	—
Operating income	82.6	66.2	15.6	35.2	50.0	62.4	16.6	+6.4	34.3	(2.6)	48.2	(3.6)	—	—	34.3	(2.6)	80.0	+28.2
(% of Revenues)	19.3	17.4	18.2	19.4	18.1	16.7	18.4	—	18.5	—	17.5	—	—	—	18.5	—	19.1	—
Non-operating income	9.4	2.4	2.1	1.3	3.3	2.3	1.1	(47.6)	1.0	(23.1)	1.2	(63.6)	—	—	1.0	(23.1)	—	—
Non-operating expenses	1.6	3.5	1.0	0.4	2.2	1.2	1.5	+50.0	1.0	+150.0	1.4	(36.4)	—	—	1.0	+150.0	—	—
Ordinary income	90.4	65.1	16.7	36.2	51.1	63.6	16.3	(2.4)	34.3	(5.2)	48.1	(5.9)	—	—	34.3	(5.2)	80.5	+26.6
(% of Revenues)	21.1	17.2	19.5	19.9	18.5	17.0	18.1	—	18.5	—	17.5	—	—	—	18.5	—	19.2	—
Extraordinary gain	0.3	0.6	—	—	0.0	0.0	0.0	—	0.0	—	0.0	—	—	—	0.0	—	—	—
Extraordinary loss	1.3	0.0	7.1	7.6	9.1	6.5	0.0	(100.0)	0.0	(100.0)	0.0	(100.0)	—	—	0.0	(100.0)	—	—
Income before income taxes etc.	89.4	65.7	9.6	28.6	42.0	57.1	16.3	+69.8	34.4	+20.3	48.1	+14.5	—	—	34.4	+20.3	—	—
(% of Revenues)	20.8	17.3	11.2	15.7	15.2	15.3	18.1	—	18.6	—	17.5	—	—	—	18.6	—	—	—
Net income	56.6	41.4	5.0	17.1	27.1	35.2	9.3	+86.0	20.9	+22.2	29.8	+10.0	—	—	20.9	+22.2	49.0	+39.2
(% of Revenues)	13.2	10.9	5.8	9.4	9.8	9.4	10.3	—	11.3	—	10.8	—	—	—	11.3	—	11.7	—

Financial Highlights (QTR)

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012								Forecast (Feb 1 st announced)			
	1-12	1-12	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)	FY2012			
	Full-year	Full-year	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR		1-6	Change (%)	7-12	Change (%)
																1st Half(Actual)	2nd Half	
Revenues	428.9	379.5	85.7	96.2	94.1	97.5	90.3	+5.4	95.0	(1.2)	90.1	(4.3)	—	—	185.3	+1.9	223.0	+16.4
Sales	419.1	375.6	80.4	94.4	92.7	96.2	86.8	+8.0	93.2	(1.3)	88.6	(4.4)	—	—	180.0	+3.0	214.2	+13.4
excl. Tamiflu	342.9	357.4	76.2	94.0	91.0	93.7	79.0	+3.7	92.9	(1.2)	88.5	(2.7)	—	—	171.9	+1.0	212.9	+15.3
Tamiflu	76.2	18.2	4.2	0.4	1.7	2.4	7.8	+85.7	0.3	(25.0)	0.1	(94.1)	—	—	8.1	+76.1	1.3	(68.3)
Ordinary sales	36.2	1.6	3.7	0.4	0.0	1.3	7.5	+102.7	0.3	(25.0)	0.1	—	—	—	7.8	+90.2	1.3	+0.0
Govt. stockpile etc.	40.0	16.6	0.5	—	1.7	1.1	0.4	(20.0)	—	—	—	(100.0)	—	—	0.4	(20.0)	—	(100.0)
Other operating revenues	9.8	3.9	5.3	1.8	1.4	1.3	3.5	(34.0)	1.8	+0.0	1.5	+7.1	—	—	5.3	(26.4)	8.8	+225.9
Cost of sales	192.9	162.4	35.1	39.4	40.8	42.1	39.6	+12.8	42.1	+6.9	39.3	(3.7)	—	—	81.7	+9.7	—	—
(% of Sales)	46.0	43.2	43.7	41.7	44.0	43.8	45.6	—	45.2	—	44.4	—	—	—	45.4	—	—	—
Gross profit	236.1	217.1	50.6	56.8	53.3	55.4	50.6	+0.0	52.9	(6.9)	50.8	(4.7)	—	—	103.5	(3.6)	—	—
(% of Revenues)	55.0	57.2	59.0	59.0	56.6	56.8	56.0	—	55.7	—	56.4	—	—	—	55.9	—	—	—
SG&A (excl. R&D) expenses	98.2	96.2	22.0	23.2	24.1	28.3	21.0	(4.5)	22.0	(5.2)	23.1	(4.1)	—	—	43.0	(5.1)	—	—
(% of Revenues)	22.9	25.3	25.7	24.1	25.6	29.0	23.3	—	23.2	—	25.6	—	—	—	23.2	—	—	—
R&D expenses	55.3	54.7	13.0	13.9	14.3	14.6	13.1	+0.8	13.2	(5.0)	13.8	(3.5)	—	—	26.2	(2.6)	—	—
(% of Revenues)	12.9	14.4	15.2	14.4	15.2	15.0	14.5	—	13.9	—	15.3	—	—	—	14.1	—	—	—
Operating income	82.6	66.2	15.6	19.6	14.8	12.4	16.6	+6.4	17.7	(9.7)	13.9	(6.1)	—	—	34.3	(2.6)	43.5	+59.9
(% of Revenues)	19.3	17.4	18.2	20.4	15.7	12.7	18.4	—	18.6	—	15.4	—	—	—	18.5	—	19.5	—
Non-operating income	9.4	2.4	2.1	1.2	2.1	1.9	1.1	(47.6)	1.5	+25.0	0.6	(71.4)	—	—	1.0	(23.1)	—	—
Non-operating expenses	1.6	3.5	1.0	1.4	2.0	1.8	1.5	+50.0	1.2	(14.3)	0.8	(60.0)	—	—	1.0	+150.0	—	—
Ordinary income	90.4	65.1	16.7	19.5	14.9	12.5	16.3	(2.4)	18.0	(7.7)	13.7	(8.1)	—	—	34.3	(5.2)	43.5	+58.8
(% of Revenues)	21.1	17.2	19.5	20.3	15.8	12.8	18.1	—	18.9	—	15.2	—	—	—	18.5	—	19.5	—
Extraordinary gain	0.3	0.6	—	—	0.0	0.0	0.0	—	0.0	—	—	—	—	—	0.0	—	—	—
Extraordinary loss	1.3	0.0	7.1	0.5	1.5	(2.6)	0.0	(100.0)	0.0	(100.0)	0.0	(100.0)	—	—	0.0	(100.0)	—	—
Income before income taxes etc.	89.4	65.7	9.6	19.0	13.4	15.2	16.3	+69.8	18.0	(5.3)	13.7	+2.2	—	—	34.4	+20.3	—	—
(% of Revenues)	20.8	17.3	11.2	19.8	14.2	15.6	18.1	—	18.9	—	15.2	—	—	—	18.6	—	—	—
Net income	56.6	41.4	5.0	12.1	10.0	8.1	9.3	+86.0	11.5	(5.0)	9.0	(10.0)	—	—	20.9	+22.2	27.0	+49.2
(% of Revenues)	13.2	10.9	5.8	12.6	10.6	8.3	10.3	—	12.1	—	10.0	—	—	—	11.3	—	12.1	—

Statements of Revenues (YTD)

(Billions of Yen)

																	Forecast (Feb 1 st announced)			
			FY2009	FY2010	FY2011				FY2012								FY2012			
			1-12	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-6	Change (%)	1-12	Change (%)
			Full-year	Full-year	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		Half-year(Actual)		Full-year	
Sales			419.1	375.6	80.4	174.8	267.5	363.6	86.8	+8.0	180.0	+3.0	268.6	+0.4	—	—	180.0	+3.0	403.7	+11.0
Excl. Tamiflu			342.9	357.4	76.2	170.2	261.2	354.9	79.0	+3.7	171.9	+1.0	260.4	(0.3)	—	—	171.9	+1.0	394.1	+11.0
Domestic			309.3	324.4	70.2	150.9	227.8	315.3	68.1	(3.0)	150.4	(0.3)	229.9	+0.9	—	—	150.4	(0.3)	353.9	+12.2
Oncology field			123.7	141.2	31.0	67.9	101.5	141.9	32.7	+5.5	72.4	+6.6	111.3	+9.7	—	—	72.4	+6.6	165.4	+16.6
Avastin			34.9	52.6	12.5	26.4	40.2	56.4	13.4	+7.2	29.6	+12.1	46.0	+14.4	—	—	29.6	+12.1	68.8	+22.0
Herceptin			29.7	25.3	5.6	13.9	18.7	25.9	6.1	+8.9	13.5	(2.9)	20.6	+10.2	—	—	13.5	(2.9)	27.3	+5.4
Rituxan			21.1	23.0	4.9	10.4	16.2	22.9	5.3	+8.2	11.7	+12.5	17.8	+9.9	—	—	11.7	+12.5	25.3	+10.5
Xeloda			6.6	10.7	2.3	4.9	7.4	10.0	2.4	+4.3	5.2	+6.1	7.9	+6.8	—	—	5.2	+6.1	16.8	+68.0
Neutrogin			11.3	10.4	1.8	4.1	6.6	9.4	1.8	+0.0	4.0	(2.4)	6.2	(6.1)	—	—	4.0	(2.4)	9.7	+3.2
Tarceva			5.8	7.9	1.7	3.8	5.8	8.3	1.9	+11.8	4.5	+18.4	6.9	+19.0	—	—	4.5	+18.4	8.2	(1.2)
Femara			2.4	3.2	0.8	1.7	2.6	3.6	0.8	+0.0	1.9	+11.8	2.9	+11.5	—	—	1.9	+11.8	4.3	+19.4
Kytril			8.6	5.5	0.8	1.7	2.5	3.4	0.6	(25.0)	1.2	(29.4)	1.8	(28.0)	—	—	1.2	(29.4)	3.1	(8.8)
Other products			3.3	2.5	0.5	1.0	1.5	2.1	0.4	(20.0)	0.8	(20.0)	1.2	(20.0)	—	—	0.8	(20.0)	1.9	(9.5)
Bone and joint diseases field			57.6	62.6	14.0	30.4	47.2	66.2	13.6	(2.9)	30.3	(0.3)	46.9	(0.6)	—	—	30.3	(0.3)	70.3	+6.2
Actemra			8.4	14.1	3.5	7.6	12.1	17.5	3.8	+8.6	7.9	+3.9	12.1	+0.0	—	—	7.9	+3.9	18.3	+4.6
Evista			17.9	18.7	3.8	8.4	13.2	18.5	3.4	(10.5)	7.6	(9.5)	11.6	(12.1)	—	—	7.6	(9.5)	16.9	(8.6)
Suvenyl			13.7	13.6	2.6	6.0	9.3	13.0	2.7	+3.8	5.9	(1.7)	9.0	(3.2)	—	—	5.9	(1.7)	14.7	+13.1
Alfarol			13.6	12.3	2.6	5.4	8.2	11.2	2.2	(15.4)	4.4	(18.5)	6.2	(24.4)	—	—	4.4	(18.5)	8.0	(28.6)
Edirol *			—	—	—	0.6	0.8	1.3	0.6	—	2.5	+316.7	4.8	+500.0	—	—	2.5	+316.7	7.8	+500.0
Other products			3.9	4.0	1.5	2.4	3.6	4.6	0.9	(40.0)	1.9	(20.8)	3.2	(11.1)	—	—	1.9	(20.8)	4.6	+0.0
Renal diseases field			61.0	57.4	11.4	24.3	36.9	50.7	10.3	(9.6)	22.9	(5.8)	34.8	(5.7)	—	—	22.9	(5.8)	62.7	+23.7
Mircera *			—	—	—	—	2.8	5.9	3.0	—	7.5	—	12.2	+335.7	—	—	7.5	—	29.6	+401.7
Epogin			44.4	40.0	7.5	16.6	22.5	28.8	3.9	(48.0)	7.7	(53.6)	11.1	(50.7)	—	—	7.7	(53.6)	16.8	(41.7)
Oxarol			10.6	12.0	2.8	5.8	8.8	12.2	2.7	(3.6)	5.9	+1.7	8.9	+1.1	—	—	5.9	+1.7	13.5	+10.7
Renagel			5.3	4.9	1.1	1.7	2.3	3.1	0.6	(45.5)	1.5	(11.8)	2.3	+0.0	—	—	1.5	(11.8)	2.3	(25.8)
Other products			0.7	0.5	0.1	0.2	0.4	0.7	0.1	+0.0	0.2	+0.0	0.4	+0.0	—	—	0.2	+0.0	0.5	(28.6)
Transplant, Immunology & Infectious diseases field			26.2	25.8	5.5	11.5	17.0	22.8	4.5	(18.2)	9.8	(14.8)	14.8	(12.9)	—	—	9.8	(14.8)	25.6	+12.3
Pegasys			11.1	10.5	2.2	4.4	6.3	8.3	1.6	(27.3)	3.4	(22.7)	5.1	(19.0)	—	—	3.4	(22.7)	12.1	+45.8
Copegus			4.9	4.5	0.9	1.9	2.6	3.3	0.5	(44.4)	1.0	(47.4)	1.5	(42.3)	—	—	1.0	(47.4)	2.7	(18.2)
CellCept			4.4	5.2	1.2	2.6	4.1	5.7	1.4	+16.7	3.1	+19.2	4.7	+14.6	—	—	3.1	+19.2	6.0	+5.3
Other products			5.8	5.7	1.2	2.6	4.0	5.5	1.1	(8.3)	2.3	(11.5)	3.5	(12.5)	—	—	2.3	(11.5)	4.7	(14.5)
Others field			40.9	37.4	8.3	16.8	25.2	33.8	6.9	(16.9)	15.0	(10.7)	22.2	(11.9)	—	—	15.0	(10.7)	30.0	(11.2)
Sigmart			14.7	13.0	2.7	5.7	8.3	11.1	2.2	(18.5)	4.7	(17.5)	6.9	(16.9)	—	—	4.7	(17.5)	9.8	(11.7)
Other products			26.3	24.4	5.6	11.0	16.9	22.6	4.8	(14.3)	10.3	(6.4)	15.3	(9.5)	—	—	10.3	(6.4)	20.1	(11.1)
Overseas			33.6	33.0	5.9	19.3	33.4	39.6	10.9	+84.7	21.5	+11.4	30.5	(8.7)	—	—	21.5	+11.4	40.2	+1.5
Actemra			8.9	12.7	1.4	9.1	18.8	20.5	6.8	+385.7	13.4	+47.3	18.2	(3.2)	—	—	13.4	+47.3	24.1	+17.6
Neutrogin			21.3	17.0	3.5	8.1	11.7	15.6	3.4	(2.9)	6.7	(17.3)	10.3	(12.0)	—	—	6.7	(17.3)	13.1	(16.0)
Sigmart			1.9	2.2	0.6	1.2	1.7	2.1	0.3	(50.0)	0.6	(50.0)	0.9	(47.1)	—	—	0.6	(50.0)	1.6	(23.8)
Other products			1.5	1.2	0.5	0.9	1.2	1.4	0.4	(20.0)	0.8	(11.1)	1.1	(8.3)	—	—	0.8	(11.1)	1.3	(7.1)
Tamiflu			76.2	18.2	4.2	4.6	6.3	8.7	7.8	+85.7	8.1	+76.1	8.2	+30.2	—	—	8.1	+76.1	9.6	+10.3
Ordinary sales			36.2	1.6	3.7	4.1	4.1	5.4	7.5	+102.7	7.8	+90.2	7.9	+92.7	—	—	7.8	+90.2	9.3	+72.2
Govt. stockpile etc.			40.0	16.6	0.5	0.5	2.2	3.3	0.4	(20.0)	0.4	(20.0)	0.4	(81.8)	—	—	0.4	(20.0)	0.3	(90.9)
Other operating revenues			9.8	3.9	5.3	7.2	8.5	9.9	3.5	(34.0)	5.3	(26.4)	6.8	(20.0)	—	—	5.3	(26.4)	14.8	+49.5
Revenues (total)			428.9	379.5	85.7	181.9	276.0	373.5	90.3	+5.4	185.3	+1.9	275.4	(0.2)	—	—	185.3	+1.9	418.5	+12.0
Domestic			392.6	342.9	77.7	159.0	237.8	327.9	78.1	+0.5	161.1	+1.3	240.8	+1.3	—	—	161.1	+1.3	371.2	+13.2
Overseas			36.4	36.6	8.0	22.9	38.2	45.6	12.2	+52.5	24.2	+5.7	34.6	(9.4)	—	—	24.2	+5.7	47.3	+3.7

Note: Edirol (launched in April 2011), Mircera (launched in July 2011)

Statements of Revenues (QTR)

(Billions of Yen)

																	Forecast (Feb 1 st announced)			
			FY2009	FY2010	FY2011				FY2012								FY2012			
			1-12	1-12	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)	1-6	Change (%)	7-12	Change (%)
			Full-year	Full-year	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR		1st Half(Actual)		2nd Half	
Sales			419.1	375.6	80.4	94.4	92.7	96.2	86.8	+8.0	93.2	(1.3)	88.6	(4.4)	—	—	180.0	+3.0	214.2	+13.4
Excl. Tamiflu			342.9	357.4	76.2	94.0	91.0	93.7	79.0	+3.7	92.9	(1.2)	88.5	(2.7)	—	—	171.9	+1.0	212.9	+15.3
Domestic			309.3	324.4	70.2	80.6	76.9	87.5	68.1	(3.0)	82.3	+2.1	79.5	+3.4	—	—	150.4	(0.3)	193.1	+17.5
Oncology field			123.7	141.2	31.0	36.8	33.7	40.4	32.7	+5.5	39.7	+7.9	38.9	+15.4	—	—	72.4	+6.6	91.0	+23.0
Avastin			34.9	52.6	12.5	13.9	13.8	16.2	13.4	+7.2	16.1	+15.8	16.4	+18.8	—	—	29.6	+12.1	38.1	+27.0
Herceptin			29.7	25.3	5.6	8.3	4.8	7.2	6.1	+8.9	7.3	(12.0)	7.1	+47.9	—	—	13.5	(2.9)	14.6	+21.7
Rituxan			21.1	23.0	4.9	5.5	5.8	6.7	5.3	+8.2	6.3	+14.5	6.1	+5.2	—	—	11.7	+12.5	14.0	+12.0
Xeloda			6.6	10.7	2.3	2.6	2.5	2.7	2.4	+4.3	2.8	+7.7	2.7	+8.0	—	—	5.2	+6.1	9.5	+86.3
Neutrogin			11.3	10.4	1.8	2.3	2.5	2.8	1.8	+0.0	2.3	+0.0	2.2	(12.0)	—	—	4.0	(2.4)	5.4	+1.9
Tarceva			5.8	7.9	1.7	2.1	2.0	2.4	1.9	+11.8	2.6	+23.8	2.4	+20.0	—	—	4.5	+18.4	4.6	+2.2
Femara			2.4	3.2	0.8	0.9	0.9	1.0	0.8	+0.0	1.1	+22.2	1.0	+11.1	—	—	1.9	+11.8	2.4	+26.3
Kytril			8.6	5.5	0.8	0.9	0.8	0.9	0.6	(25.0)	0.6	(33.3)	0.6	(25.0)	—	—	1.2	(29.4)	1.5	(11.8)
Other products			3.3	2.5	0.5	0.5	0.5	0.5	0.4	(20.0)	0.5	+0.0	0.4	(20.0)	—	—	0.8	(20.0)	0.9	(10.0)
Bone and joint diseases field			57.6	62.6	14.0	16.4	16.8	19.0	13.6	(2.9)	16.7	+1.8	16.6	(1.2)	—	—	30.3	(0.3)	38.9	+8.7
Actemra			8.4	14.1	3.5	4.1	4.5	5.4	3.8	+8.6	4.2	+2.4	4.2	(6.7)	—	—	7.9	+3.9	10.5	+6.1
Evista			17.9	18.7	3.8	4.6	4.8	5.3	3.4	(10.5)	4.2	(8.7)	3.9	(18.8)	—	—	7.6	(9.5)	8.9	(11.9)
Suvenyl			13.7	13.6	2.6	3.4	3.3	3.7	2.7	+3.8	3.2	(5.9)	3.0	(9.1)	—	—	5.9	(1.7)	7.9	+12.9
Alfarol			13.6	12.3	2.6	2.8	2.8	3.1	2.2	(15.4)	2.2	(21.4)	1.8	(35.7)	—	—	4.4	(18.5)	4.2	(27.6)
Edirol			—	—	—	0.6	0.2	0.5	0.6	—	1.9	+216.7	2.3	+1,050.0	—	—	2.5	+316.7	5.0	+614.3
Other products			3.9	4.0	1.5	0.9	1.2	1.0	0.9	(40.0)	1.0	+11.1	1.4	+16.7	—	—	1.9	(20.8)	2.5	+8.7
Renal diseases field			61.0	57.4	11.4	12.9	12.6	13.8	10.3	(9.6)	12.5	(3.1)	11.9	(5.6)	—	—	22.9	(5.8)	34.3	+29.9
Mircera			—	—	—	—	2.8	3.1	3.0	—	4.5	—	4.6	+64.3	—	—	7.5	—	17.5	+196.6
Epogin			44.4	40.0	7.5	9.1	6.0	6.3	3.9	(48.0)	3.8	(58.2)	3.4	(43.3)	—	—	7.7	(53.6)	8.1	(33.6)
Oxarol			10.6	12.0	2.8	3.0	3.0	3.4	2.7	(3.6)	3.2	+6.7	3.0	+0.0	—	—	5.9	+1.7	7.3	+14.1
Renagel			5.3	4.9	1.1	0.7	0.6	0.7	0.6	(45.5)	0.9	+28.6	0.8	+33.3	—	—	1.5	(11.8)	1.2	(7.7)
Other products			0.7	0.5	0.1	0.1	0.2	0.3	0.1	+0.0	0.1	+0.0	0.1	(50.0)	—	—	0.2	+0.0	0.2	(60.0)
Transplant, Immunology & Infectious diseases field			26.2	25.8	5.5	6.0	5.4	5.8	4.5	(18.2)	5.3	(11.7)	5.0	(7.4)	—	—	9.8	(14.8)	13.6	+21.4
Pegasys			11.1	10.5	2.2	2.3	1.9	2.0	1.6	(27.3)	1.8	(21.7)	1.7	(10.5)	—	—	3.4	(22.7)	6.6	+69.2
Copegus			4.9	4.5	0.9	1.0	0.7	0.7	0.5	(44.4)	0.6	(40.0)	0.4	(42.9)	—	—	1.0	(47.4)	1.5	+7.1
CellCept			4.4	5.2	1.2	1.4	1.4	1.6	1.4	+16.7	1.6	+14.3	1.6	+14.3	—	—	3.1	+19.2	3.3	+6.5
Other products			5.8	5.7	1.2	1.4	1.4	1.5	1.1	(8.3)	1.2	(14.3)	1.2	(14.3)	—	—	2.3	(11.5)	2.3	(20.7)
Others field			40.9	37.4	8.3	8.4	8.4	8.5	6.9	(16.9)	8.1	(3.6)	7.2	(14.3)	—	—	15.0	(10.7)	15.2	(10.6)
Sigmar			14.7	13.0	2.7	3.0	2.6	2.8	2.2	(18.5)	2.5	(16.7)	2.2	(15.4)	—	—	4.7	(17.5)	5.2	(3.7)
Other products			26.3	24.4	5.6	5.4	5.9	5.7	4.8	(14.3)	5.6	+3.7	4.9	(16.9)	—	—	10.3	(6.4)	10.0	(13.8)
Overseas			33.6	33.0	5.9	13.4	14.1	6.3	10.9	+84.7	10.6	(20.9)	9.0	(36.2)	—	—	21.5	+11.4	19.8	(2.5)
Actemra			8.9	12.7	1.4	7.7	9.7	1.7	6.8	+385.7	6.6	(14.3)	4.8	(50.5)	—	—	13.4	+47.3	11.8	+3.5
Neutrogin			21.3	17.0	3.5	4.6	3.6	3.9	3.4	(2.9)	3.3	(28.3)	3.6	+0.0	—	—	6.7	(17.3)	6.6	(12.0)
Sigmar			1.9	2.2	0.6	0.6	0.5	0.4	0.3	(50.0)	0.3	(50.0)	0.3	(40.0)	—	—	0.6	(50.0)	0.8	(11.1)
Other products			1.5	1.2	0.5	0.4	0.3	0.3	0.4	(20.0)	0.4	+0.0	0.3	+0.0	—	—	0.8	(11.1)	0.6	+0.0
Tamiflu			76.2	18.2	4.2	0.4	1.7	2.4	7.8	+85.7	0.3	(25.0)	0.1	(94.1)	—	—	8.1	+76.1	1.3	(68.3)
Ordinary sales			36.2	1.6	3.7	0.4	0.0	1.3	7.5	+102.7	0.3	(25.0)	0.1	—	—	—	7.8	+90.2	1.3	+0.0
Govt. stockpile etc.			40.0	16.6	0.5	—	1.7	1.1	0.4	(20.0)	—	—	—	(100.0)	—	—	0.4	(20.0)	—	(100.0)
Other operating revenues			9.8	3.9	5.3	1.8	1.4	1.3	3.5	(34.0)	1.8	+0.0	1.5	+7.1	—	—	5.3	(26.4)	8.8	+225.9
Revenues (total)			428.9	379.5	85.7	96.2	94.1	97.5	90.3	+5.4	95.0	(1.2)	90.1	(4.3)	—	—	185.3	+1.9	223.0	+16.4
Domestic			392.6	342.9	77.7	81.3	78.8	90.1	78.1	+0.5	83.0	+2.1	79.7	+1.1	—	—	161.1	+1.3	199.5	+18.1
Overseas			36.4	36.6	8.0	14.9	15.3	7.4	12.2	+52.5	12.0	(19.5)	10.4	(32.0)	—	—	24.2	+5.7	23.5	+3.5

Balance Sheets

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012					
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	vs. Sep. 30, 2011	vs. Dec. 31, 2011	As of Dec. 31
Cash and deposits	107.0	76.2	101.7	109.2	110.7	107.2	123.1	130.0	97.1	(13.6)	(10.1)	–
Trade notes and accounts receivable	121.6	113.4	94.6	105.8	98.4	110.9	94.6	99.5	99.8	+1.4	(11.1)	–
Marketable securities	52.2	59.7	58.0	59.0	59.0	61.0	67.0	71.0	101.0	+42.0	+40.0	–
Inventories	92.6	104.9	108.5	110.4	115.7	105.0	101.2	99.4	101.3	(14.4)	(3.7)	–
Other current assets	37.9	32.3	39.7	27.6	33.9	35.4	35.1	31.0	33.8	(0.1)	(1.6)	–
Total Current assets	411.3	386.5	402.5	412.1	417.7	419.4	421.1	430.8	433.0	+15.3	+13.6	–
Property, plant and equipment	93.7	88.0	86.1	83.5	81.8	82.9	80.9	81.9	82.2	+0.4	(0.7)	–
Intangible assets	3.2	2.4	2.3	2.4	2.1	2.0	1.9	1.7	1.7	(0.4)	(0.3)	–
Investments and other assets	32.3	31.2	29.3	31.3	32.8	29.2	28.5	27.7	27.3	(5.5)	(1.9)	–
thereof Investment securities	9.7	7.6	7.0	6.9	6.9	6.4	6.6	6.0	5.8	(1.1)	(0.6)	–
Total Noncurrent Assets	129.2	121.5	117.8	117.3	116.7	114.1	111.4	111.3	111.1	(5.6)	(3.0)	–
Total Assets	540.5	508.0	520.3	529.4	534.4	533.5	532.5	542.2	544.1	+9.7	+10.6	–
Trade notes and accounts payable	34.3	19.5	29.5	28.5	29.2	17.4	23.9	26.8	29.2	0.0	+11.8	–
Short-term loans and bonds	–	–	–	–	–	–	–	–	–	–	–	–
Other current liabilities	66.2	35.1	42.4	40.3	48.1	51.5	42.3	40.6	41.4	(6.7)	(10.1)	–
Total current liabilities	100.5	54.6	72.0	68.8	77.3	68.8	66.2	67.3	70.6	(6.7)	+1.8	–
Long-term debt and bonds	–	–	–	–	–	–	–	–	–	–	–	–
Other noncurrent liabilities	5.4	4.0	5.3	5.3	5.4	5.6	5.5	5.5	5.8	+0.4	+0.2	–
Total noncurrent liabilities	5.4	4.0	5.3	5.3	5.4	5.6	5.5	5.5	5.8	+0.4	+0.2	–
Total liabilities	105.9	58.6	77.3	74.1	82.8	74.4	71.7	72.8	76.4	(6.4)	+2.0	–
Common stock	73.0	73.0	73.0	73.0	73.0	73.0	73.0	73.0	73.0	–	–	–
Capital surplus	92.8	92.8	92.8	92.8	92.8	92.8	92.8	92.8	92.8	–	–	–
Retained earnings	308.0	327.6	320.1	332.2	331.4	339.5	338.0	349.6	347.6	+16.2	+8.1	–
Treasury stock, at cost	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	(36.2)	(36.2)	+0.1	+0.1	–
Net unrealized gain or loss on securities	1.6	1.3	1.0	0.9	1.1	0.8	1.6	1.4	1.3	+0.2	+0.5	–
Deferred gains or losses on hedges	–	–	–	–	–	–	0.3	(0.2)	0.0	0.0	0.0	–
Foreign currency translation adjustments	(6.8)	(11.3)	(9.5)	(9.7)	(12.2)	(13.0)	(10.9)	(13.3)	(13.0)	(0.8)	0.0	–
Subscription rights to shares	0.5	0.8	0.8	0.9	0.9	1.0	1.1	1.1	1.2	+0.3	+0.2	–
Minority interests	1.8	1.4	1.0	1.4	1.0	1.2	1.1	1.2	0.9	(0.1)	(0.3)	–
Total net assets	434.7	449.4	443.0	455.3	451.6	459.1	460.8	469.4	467.7	+16.1	+8.6	–
Total liabilities and net assets	540.5	508.0	520.3	529.4	534.4	533.5	532.5	542.2	544.1	+9.7	+10.6	–

Cash Flows

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012			
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year
Net cash provided by (used in) operating activities	66.5	15.6	39.6	50.2	67.8	69.6	34.0	50.3	62.2	—
Net cash provided by (used in) investing activities	(20.3)	(20.2)	(0.8)	(3.7)	(6.4)	(15.1)	(8.8)	(15.9)	(51.5)	—
Net cash provided by (used in) financing activities	(22.3)	(23.1)	(13.2)	(13.2)	(24.3)	(24.6)	(11.1)	(11.3)	(22.5)	—
Effect of exchange rate changes on cash and cash equivalents	(0.1)	(1.7)	0.7	0.6	(0.7)	(0.6)	0.7	(0.1)	0.1	—
Net increase (decrease) in cash and cash equivalents	23.8	(29.3)	26.4	34.0	36.5	29.3	14.9	23.0	(11.8)	—
Cash and cash equivalents at beginning of period	70.7	94.5	65.1	65.1	65.1	65.1	94.5	94.5	94.5	—
Cash and cash equivalents at end of period	94.5	65.1	91.6	99.1	101.7	94.5	109.4	117.5	82.7	—

Performance Indicators

	FY2009	FY2010	FY2011				FY2012				Forecast (Feb 1 st announced)
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2012
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Net income per share (Basic)	104.00yen	76.14yen	9.17yen	31.40yen	49.85yen	64.75yen	17.17yen	38.39yen	54.83yen	—	90.04yen
Net income per share (Fully diluted) *1	103.98yen	76.12yen	9.17yen	31.39yen	49.84yen	64.73yen	17.16yen	38.37yen	54.81yen	—	—
Ratio of net income to shareholders' equity *2	13.7%	9.4%	1.1%	3.8%	6.0%	7.8%	2.0%	4.5%	6.5%	—	—
Ratio of ordinary income to total assets *2	17.7%	12.4%	3.2%	7.0%	9.8%	12.2%	3.1%	6.4%	8.9%	—	—
Net assets per share	794.51yen	821.87yen	810.62yen	832.45yen	826.39yen	839.50yen	842.68yen	858.26yen	855.58yen	—	—
Equity ratio	80.0%	88.0%	84.8%	85.6%	84.2%	85.6%	86.1%	86.2%	85.6%	—	—
Dividend per share (Annual)	40yen	40yen				40yen				—	40yen
Dividend per share (Interim)	17yen	17yen				20yen				20yen	20yen
Dividend payout ratio (Consolidated)	38.5%	61.8%				61.8%				—	44.4%

Notes: 1. "Accounting Standard for Earnings Per Share" (Accounting Standards Board of Japan (ASBJ) Statement No. 2, revised on June 30, 2010) and "Guidance on Accounting Standard for Earnings Per Share" (ASBJ Guidance No. 4, revised on June 30, 2010) are applied to the amounts for FY2011 and FY2012.
2. Quarterly (year-to-date) Ratio of net income to shareholders' equity and Ratio of ordinary income to total assets are not annualized.

Number of Employees

	FY2009	FY2010	FY2011				FY2012				Forecast (Feb 1 st announced)
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2012
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Number of employees	6,485	6,709	6,635	6,818	6,812	6,779	6,760	6,886	6,863	—	6,900

Note: Number of employees doesn't include staff seconded to companies outside the Group.

Capital Expenditures

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012				Forecast (Feb 1 st announced)
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2012
	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year	Full-year
Capital expenditures	14.6	12.7	1.4	4.6	6.4	11.9	1.2	5.7	10.0	—	18.0
Depreciation	19.5	18.0	3.8	7.2	11.4	15.9	3.5	7.1	11.1	—	16.0

Development pipeline (as of October 23, 2012)

Development code (Compound number)	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Oncology</u>					
RG1273 (RO4368451)	Breast cancer	Filed (12/05)	pertuzumab	Roche Perjeta	Humanized HER dimerization inhibitory monoclonal antibody
	Breast cancer (adjuvant)	Phase III Multinational study	Injection		
RG1415 (RO50-8231)	Non-small cell lung cancer (1st line) #	Filed (12/06)	erlotinib HCl Tarceva Oral	Roche / OSI Tarceva	EGFR tyrosine kinase inhibitor
RG435 (RO4876646)	Recurrent glioblastoma #	Filed (12/09)	bevacizumab Avastin Injection	Roche Avastin	Anti-VEGF(Vascular Endothelial Growth Factor) humanized monoclonal antibody
	Ovarian cancer #	Filed (12/10)			
	Glioblastoma #	Phase III Multinational study			
	Breast cancer (adjuvant) #	Phase III Multinational study			
	Gastric cancer #	Phase III			
RG3502 (RO5304020)	Breast cancer	Phase III Multinational study	trastuzumab emtansine Injection	Roche	HER2 antibody-drug conjugate (T-DM1)
	Gastric cancer	Phase II / III Multinational study			
RG3638 (RO5490258/PRO143 966)	Non-small cell lung cancer	Phase III Multinational study	onartuzumab Injection	Roche	Humanized anti-Met monoclonal antibody (MetMAb)
GA101 / RG7159 (RO5072759)	Indolent NHL	Phase III Multinational study	obinutuzumab Injection	Roche	Humanized anti-CD20 monoclonal antibody
	Aggressive NHL	Phase III Multinational study			
GC33 / RG7686 (GC33/RO5137382)	Liver cancer	Phase II Multinational study	Injection	In-house (Roche)	Humanized anti-Glypican-3 monoclonal antibody

Development code (Compound number)	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG340 (Ro09-1978)	Gastric cancer (adjuvant) #	Phase II	capecitabine Xeloda Oral	Roche Xeloda (Yakult Honsha)	Antimetabolite, 5-FU derivative
AF802 (CH5424802)	Non-small cell lung cancer	Phase I / II	Oral	In-house	ALK inhibitor
		Phase I / II Overseas			
WT4869 (WT4869)	Myelodysplastic syndromes	Phase I / II	Injection	In-house / Dainippon Sumitomo Pharma	WT1 peptide cancer vaccine
	Solid tumors	Phase I			
WT2725 (WT2725)	Advanced cancer	Phase I Overseas	Injection	In-house / Dainippon Sumitomo Pharma	WT1 peptide cancer vaccine
CIF / RG7167 (RO4987655)	Solid tumors	Phase I	Oral	In-house	MEK inhibitor
		Phase I Overseas		(Roche)	
CKI27 / RG7304 (RO5126766)	Solid tumors	Phase I	Oral	In-house	Raf and MEK dual inhibitor
		Phase I Overseas		(Roche)	
PA799 (CH5132799)	Solid tumors	Phase I Overseas	Oral	In-house	PI3K class I inhibitor
RG7204 (RO5185426)	Melanoma	Phase I	vemurafenib Oral	Roche Zelboraf	BRAF inhibitor
<u>Bone and Joint Diseases</u>					
RG484 (Ro200-5450iv) (Ro200-5450po)	Osteoporosis	Filed (12/07)	ibandronate sodium hydrate Injection	Roche Boniva (US) / Bonviva (EU) (Taisho Pharmaceutical)	Bisphosphonate
		Phase III	ibandronate sodium hydrate Oral		
NRD101 (NRD101)	Enthesopathy (Lateral epicondylitis, Patellar tendinitis, Achilles tendinopathy, Plantar fasciitis)	Phase III	sodium hyaluronate Suvenyl Injection	In-house	Sodium hyaluronate

Development code (Compound number)	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Autoimmune Diseases</u>					
MRA (MRA-SC)	Rheumatoid arthritis (new formulation: subcutaneous injection)	Filed (12/03)	tocilizumab Actemra / RoActemra(EU) Injection	In-house (Roche)	Humanized anti-human IL-6 receptor monoclonal antibody
		Phase III Overseas			
SA237 (SA237)	Rheumatoid arthritis	Phase I	Injection	In-house	Humanized anti-human IL-6 receptor monoclonal antibody
RG7415 (PRO155767)	Systemic lupus erythematosus (SLE)	Phase I	rontalizumab Injection	Roche	Humanized anti-interferon alpha monoclonal antibody
<u>Diabetes Mellitus</u>					
CSG452 (CSG452)	Type II diabetes	Phase III	tofogliflozin hydrate Oral	In-house	SGLT2 inhibitor
<u>Central Nervous System</u>					
RG1678 (RO4917838)	Schizophrenia	Phase III Multinational study	bitopertin Oral	Roche	Glycine reuptake inhibitor
RG7090 (RO4917523)	Major depressive disorder	Phase II Multinational study	Oral	Roche	mGluR5 antagonist
RG1450 (RO4909832)	Alzheimer's disease	Phase I	gantenerumab Injection	Roche/Morphosys	Human anti-amyloid-beta monoclonal antibody
<u>Respiratory Diseases</u>					
RG3637 (RO5490255)	Asthma	Phase I	lebrikizumab Injection	Roche	Humanized anti-IL-13 monoclonal antibody
<u>Others</u>					
CIM331 (CIM331)	Atopic dermatitis	Phase I	Injection	In-house	-

Development code (Compound number)	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
ACE910 (ACE910)	Hemophilia A	Phase I	Injection	In-house	Anti-factor IXa x anti-factor X humanized bispecific antibody

Changes from the last announcement on July 26, 2012

Oncology

- RG435 Phase II → Filed (Recurrent glioblastoma)
- RG435 Filed (Ovarian cancer)
- RG3638 Phase I → Phase III multinational study (Non-small cell lung cancer)
- RG3502 Phase II/III multinational study (Gastric cancer: Starting development)
- WT2725 Phase I (Advanced cancer (overseas): Starting development)
- RG7204 Phase I (Melanoma: Starting development)

Bone and Joint Diseases

- RG484 (Oral) Phase II → Phase III (Osteoporosis)

Others

- ACE910 Phase I (Hemophilia A: Starting development)

R&D Activities (Jul. 1, 2012 – Oct. 23, 2012)

As for clinical development activities in Japan, the Company saw progress as described below:

Oncology

- We filed an application for additional indication of an anti-VEGF humanized monoclonal antibody, RG435 (product name: Avastin) for recurrent glioblastoma in September, and for ovarian cancer in October 2012.
- We decided to participate in Phase III multinational study (expected indication: non-small cell lung cancer) for a humanized anti-Met monoclonal antibody, RG3638.
- In September 2012, we started a Phase II/III multinational study (expected indication: gastric cancer) for a HER2 antibody-drug conjugate, RG3502.
- In September 2012, we started a Phase I study (expected indication: melanoma) for a BRAF inhibitor, RG7204.

Bone and Joint Diseases

- In October 2012, we started a Phase III study (expected indication: osteoporosis) for a bisphosphonate, RG484 (Oral).

Others

- In August 2012, we started Phase I study (expected indication: Hemophilia A) for an anti-factor IXa x anti-factor X humanized bispecific antibody, ACE910.

Also, as for development activities overseas, the Company saw progress as described below:

- In August 2012, we started Phase I study (expected indication: advanced cancer) for a WT1 peptide cancer vaccine, WT2725.
- In October 2012, Roche obtained an approval for a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra), for expanded indication of rheumatoid arthritis (DMARDs-IR) in US.

Major clinical trials in oncology field currently running in Japan

Theme	Expected Indication	Regimen	Stage	Planned Filing Date
RG1273 (pertuzumab)	Breast cancer (1st line)	RG597 + docetaxel ± RG1273	Filed in May 2012	-
	Breast cancer (adjuvant)	RG597 + chemotherapy ± RG1273	APHINITY study Phase III multinational study	Post 2015
RG1415 (erlotinib HCL) Tarceva	Non-small cell lung cancer (1st line)	RG1415	Filed in Jun. 2012	-
RG435 (bevacizumab) Avastin	Recurrent glioblastoma	RG435	Filed in Sep. 2012	-
	Glioblastoma (1st line)	temozolomide ± RG435	AVAglio study Phase III multinational study	2014
	Breast cancer (adjuvant)	standard chemotherapy ± RG435	BEATRICE study Phase III multinational study	-
RG3502 (trastuzumab emtansine)	Breast cancer (1st line)	RG3502 ± RG1273	MARIANNE study Phase III multinational study	2013
	Breast cancer (2nd line)	RG3502	Phase II	2013
	Gastric cancer	RG3502 + chemotherapy	Phase II/III multinational study	Post 2015
GA101/ RG7159 (obinutuzumab)	Indolent NHL	GA101 + chemotherapy vs rituximab + chemotherapy (G-chemo vs R-chemo)	GALLIUM study Phase III multinational study	Post 2015
	Aggressive NHL	GA101 + CHOP vs rituximab + CHOP (G-CHOP vs R-CHOP)	GOYA study Phase III multinational study	Post 2015
RG340 (capecitabine) Xeloda	Gastric cancer (adjuvant)	RG340 + oxaliplatin	Phase II	2014